ClinicalTrials.gg
Not yet recruitingNCT07271732SXC-CSVDUpdated Dec 9, 2025

Songling Xuemaikang Capsules for Cerebral Small Vessel Disease

An interventional study of Songling Xuemaikang Capsule and Songling Xuemaikang Capsule Placebo in Hypertension and Cerebral Small Vessel Diseases, sponsored by Dongzhimen Hospital, Beijing. Not yet recruiting at 1 site in China. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Dongzhimen Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
236th of 308
90 · median 253
Started
2025
with 47 others
No phase
146 of 410
56 open now
Primary completion
2026-12
later than 65 of 147 live
Registered
351st of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 236th largest by planned enrollment of the 308 interventional ones that give a count, is one of 48 that started in 2025, is one of 146 with no phase, reaches primary completion later than 65 of the 147 other live ones, and was the 351st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

Cerebral small vessel disease (CSVD) is a common age-related microvascular disease related to the slow accumulation of damage to small arteries, veins, and capillaries. Hypertension is a risk factor for cerebrovascular disease, and its damage to the vascular endothelium is one of the key contributing factors to the pathogenesis of CSVD. CSVD has an insidious onset, and patients may exhibit no clinical symptoms in the early stage. Common clinical manifestations of chronic CSVD include vascular dementia, depression, gait disturbance, and abnormalities in swallowing and urinary functions. There is currently no specific treatment for CSVD.

Existing studies have shown that Songling Xuemaikang capsule (SXC) combined with antihypertensive drugs exerted significant effects on systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour SBP, and 24-hour DBP, while also improving symptoms of hypertension. Animal experiments have demonstrated that SXC can reduce apoptosis and alleviate cerebral ischemia-reperfusion injury, exerting neuroprotective effects. Additionally, a previously completed multicenter, randomized, double-blind, non-inferiority-designed clinical trial by the team, conducted in patients with primary hypertension, showed that SXC were non-inferior to losartan potassium in reducing diastolic blood pressure. Therefore, exploring the therapeutic potential of SXC in CSVD is highly necessary.

This project is a randomized, double-blind, placebo-controlled multicenter clinical study to investigate the clinical efficacy and safety of SXC in the treatment of hypertension with CSVD. A total of 90 subjects who met the subject screening criteria are planned to be enrolled, with 45 patients in the test group and 45 patients in the placebo group.

03

Conditions studied

  • Hypertension
  • Cerebral Small Vessel Diseases
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 55-75 years (both inclusive);
  2. MRI has moderate to (1) severe white matter lesions (deep Fazekas score > 1 or paraventricular Fazekas score > 2 or modified Fazekas score > 1), or (2) mild white matter hyperintensity (deep Fazekas score = 1 or paraventricular Fazekas score = 2 or modified Fazekas score = 1) combined with more than 1 lacunar infarction;
  3. History of essential hypertension; Hypertension is defined as SBP consistently greater than 140 mmHg and/or DBP consistently greater than 90 mmHg, or those requiring clinical antihypertensive treatment.
  4. Meeting the diagnostic criteria for hyperactivity of liver yang pattern; Hyperactivity of liver yang pattern is defined as having at least three of the following six symptoms: headache, dizziness or vertigo, irritability, flushed face, red eyes, and yellow tongue coating.
  5. Functional independence in daily living (Modified Rankin Scale ≤2);
  6. Voluntary participation in the study and be willing to sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with acute ischemic stroke or acute intracranial hemorrhage (e.g., epidural hematoma, subdural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, etc.) or a history of cerebral infarction (non-lacunar) or intracranial hemorrhage within the past 3 months;
  2. Symptomatic stenosis of the middle cerebral artery and/or internal carotid artery (stenosis rate ≥50%), or asymptomatic stenosis of the middle cerebral artery and/or internal carotid artery (stenosis rate ≥70%);
  3. Untreated cerebrovascular malformations or intracranial aneurysms (diameter >3 mm);
  4. Significant non-vascular white matter lesions (e.g., multiple sclerosis, adult-onset leukoencephalopathy, metabolic encephalopathy, etc.);
  5. Patients with a history of cognitive impairment due to other causes (e.g., normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, encephalitis, etc.);
  6. A history of intracranial or intramedullary surgery within the past year;
  7. Severe hepatic, renal, or cardiac insufficiency ( or AST >2 times the , or serum creatinine >1.5 times the upper limit of normal, or [NYHA] functional class III or IV);
  8. Severe three-vessel coronary artery disease as shown by coronary computed tomography angiography or coronary angiography within 90 days or suffering from frequent angina;
  9. hyperglycemia uncontrolled by medication (fasting blood glucose >10 mmol/L, or >8.0%);
  10. Patients with severe diseases such as cancer and a of less than 2 years;
  11. Patients with psychiatric disorders that affect study medication administration and evaluation;
  12. Previous allergy or intolerance to Songling Xuemaikang Capsules;
  13. to MRI examination (e.g., claustrophobia, presence of an implantable pacemaker, etc.);
  14. Patients unable to comply with follow-up examinations or other study procedures due to residential location or other reasons;
  15. Participation in other clinical trial projects.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Test group

    Songling Xuemaikang Capsule, 3 capsules/time, tid, p.o

    Drug: Songling Xuemaikang Capsule

  • Placebo comparator
    Control group

    Songling Xuemaikang Capsule placebo, 3 capsules/time, tid, p.o

    Drug: Songling Xuemaikang Capsule Placebo

Interventions

  • DrugSongling xuemaikangStudies of Songling xuemaikangSongling xuemaikang pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)

  • DrugSongling Xuemaikang Capsule Placebo

    3 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)

06

What researchers measure

Primary outcomes

  1. Changes in the volume of white matter hyperintensities at 1 year.

    Measure changes in the volume of white matter hyperintensities on brain MRI

    Time frame: 1 year

Secondary outcomes

  1. Change from baseline in Mini-Mental State Examination (MMSE) at 1 year;

    Change from baseline in Mini-Mental State Examination (MMSE). Score range is 0-30. Higher score means good cognition.

    Time frame: 1 year

  2. Change from baseline in Hamilton Anxiety Scale (HAMA) at 1 year;

    Change from baseline in Hamilton Anxiety Scale (HAMA).Score range is 0-56. Higher score means a more severe state of anxiety.

    Time frame: 1 year

  3. Change from baseline in Hamilton Depression Scale (HAMD) at 1 year;

    Change from baseline in Hamilton Depression Scale (HAMD). Score range is 0-76. Higher score means a more severe state of anxiety.

    Time frame: 1 year

  4. Change from baseline in Pittsburgh Sleep Quality Index (PSQI) at 1 year;

    Change from baseline in Pittsburgh Sleep Quality Index (PSQI) at 1 year. Score range is 0-21. Higher score means worse sleep quality.

    Time frame: 1 year

  5. Change from baseline in Barthel Index (BI) at 1 year;

    Change from baseline in Barthel Index (BI). Score range is 0-100. Higher score means good physical activities of daily living.

    Time frame: 1 year

  6. Feasibility of recruitment and retention

    The feasibility is defined as \>95% of randomized patients retained at 1 year

    Time frame: 1 year

  7. Change from baseline in the symptom of hyperactivity of liver yang pattern at 1 year;

    Change from baseline in the symptom of hyperactivity of liver yang pattern, which are headache, dizziness or vertigo, irritability, flushed face, red eyes, and yellow tongue coating. The study plans to analyze whether there are statistically significant differences in the incidence of the above six symptoms before and after treatment. On the other hand, for headache, dizziness or vertigo, irritability, if they do not resolve at follow-up time points, patient-reported outcomes (PROs) will be used to record the degree of change in patients' symptoms from baseline (expressed as a percentage, with \>100% indicating symptom worsening and \<100% indicating symptom relief), and statistical analysis will be carried out. For flushed face, red eyes, and yellow tongue coating, binary analysis will be performed based solely on their presence or absence.

    Time frame: 1 year

  8. Change from baseline in the mean 24h systolic blood pressure at 1 year;

    Change from baseline in the mean 24h systolic blood pressure

    Time frame: 1 year

  9. Change from baseline in the mean 24h diastolic blood pressure at 1 year;

    Change from baseline in the mean 24h diastolic blood pressure

    Time frame: 1 year

  10. Change from baseline in the mean daytime systolic blood pressure at 1 year;

    Change from baseline in the mean daytime systolic blood pressure

    Time frame: 1 year

  11. Change from baseline in the mean daytime diastolic blood pressure at 1 year;

    Change from baseline in the mean daytime diastolic blood pressure

    Time frame: 1 year

  12. Change from baseline in the mean nighttime systolic blood pressure at 1 year

    Change from baseline in the mean nighttime systolic blood pressure

    Time frame: 1 year

  13. Change from baseline in the mean nighttime diastolic blood pressure at 1 year

    Change from baseline in the mean nighttime diastolic blood pressure

    Time frame: 1 year

  14. Change from baseline in the mean 24h pulse pressure at 1year

    Change from baseline in the mean 24h pulse pressure

    Time frame: 1 year

  15. Change from baseline in the blood pressure load at 1 year

    Change from baseline in the blood pressure load

    Time frame: 1 year

  16. Change from baseline in the official systolic blood pressure at 1 year

    Change from baseline in the official systolic blood pressure

    Time frame: 1 year

  17. Change from baseline in the official diastolic blood pressure at 1 year

    Change from baseline in the official diastolic blood pressure

    Time frame: 1 year

  18. Change from baseline in the official pulse pressure at 1year

    Change from baseline in the official pulse pressure

    Time frame: 1 year

  19. Change from baseline in the official blood pressure compliance rate at 1 year

    Change from baseline in the official blood pressure compliance rate

    Time frame: 1 year

Other outcomes

  1. Numbers in new vascular events from baseline to 1 year

    New vascular events include ischemic stroke, TIA, cerebral hemorrhage, MI, pulmonary embolism, thrombosis, peripheral arterial occlusion

    Time frame: 1 year

  2. Numbers in all-cause hospitalization from baseline to 1 year

    Numbers in all-cause hospitalization

    Time frame: 1 year

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2025
First posted
Dec 9, 2025
StartEst.
Dec 10, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07271732
Lead sponsor
Dongzhimen Hospital, Beijing
Responsible party
Ying Gao (Prof., Dongzhimen Hospital, Beijing) — Principal investigator
First posted
Dec 9, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 9, 2025

Study contacts

Xinxing Lai, PhD
Contact
new-star@163.com
+86-15901111280

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Songling xuemaikang

Start the discussion